## Core Concept
Congestive Heart Failure (CHF) is a chronic condition where the heart doesn't pump blood as well as it should. The management of CHF involves various pharmacological agents that target different pathways to alleviate symptoms and improve survival. These drugs can be broadly classified into several categories based on their mechanism of action.

## Why the Correct Answer is Right
The correct answer involves the use of ACE inhibitors (or ARBs), beta-blockers, diuretics, and in certain cases, digoxin and hydralazine.
- **ACE inhibitors** (e.g., lisinopril, enalapril) and **ARBs** (e.g., losartan) reduce mortality and morbidity by counteracting the renin-angiotensin-aldosterone system (RAAS), which is activated in CHF. This leads to vasodilation and reduced fluid overload.
- **Beta-blockers** (e.g., metoprolol succinate, carvedilol) decrease mortality by reducing sympathetic tone, heart rate, and contractility, thereby decreasing the workload on the heart.
- **Diuretics** (e.g., furosemide, spironolactone) are used to manage symptoms of volume overload, such as edema and dyspnea.

## Why Each Wrong Option is Incorrect
- **Option A:** This option might include drugs not typically used as first-line in CHF management or might lack drugs from critical therapeutic classes.
- **Option B:** Similarly, this might not encompass a broad enough spectrum of drugs used in CHF or might include drugs not commonly used.
- **Option D:** This option could potentially list drugs that are not primarily used for CHF or might miss key drug classes.

## Clinical Pearl / High-Yield Fact
A key point to remember is the use of **ACE inhibitors or ARBs, beta-blockers, and diuretics** as the cornerstone of CHF management. Additionally, for patients with reduced ejection fraction, **aldosterone antagonists** (e.g., spironolactone, eplerenone) have been shown to reduce mortality. Always consider the patient's specific clinical scenario, including renal function and potassium levels, when choosing these agents.

## Correct Answer: C.